The top 5 of 2012's most-read articles all feature topics in medicine and pharmacology. However, EuroBiotechNews also reports about new developments in industrial and agricultural biotechnology as well as research politics in general. This is reflected by the most-read articles No. 8 and No. 11. Baltic biotech attracts investors is an exclusive conference report about the first Life Science Baltics conference. Study claims GMO cancer risk picks up one of the most controversial discussion in 2012: the safety of genetically modified maize.
We hope that you will join us again in 2013 as your source of breaking biotech news.
EuroBiotechNews wishes you a Merry Christmas and a happy New Year! We will be back with daily news and a packed calendar on Wednesday 2nd January.
16.04.2015 The Swiss biotech industry can look back on 2014 as a good year, but political uncertainties do remain. This was one of the topics discussed during the Swiss Biotech Day in Basel, which attracted more than 400 participants.
14.04.2015 Belgian Thrombogenics NV has launched a new oncology company with Gent-based life sciences institute VIB. The new venture will develop an antibody for the treatment of a fast-growing brain tumour that affects children and adolescents.